NasdaqGS - Nasdaq Real Time Price USD

Dyne Therapeutics, Inc. (DYN)

24.73

+1.03

(+4.37%)

At close: April 26 at 4:00 PM EDT

24.73

0.00

(0.00%)

After hours: April 26 at 4:20 PM EDT

Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has granted an inducement equity award to its newly appointed President and Chief Executive Officer, John G. Cox. The award was approved by the Compensation Committee of Dyne and was made as an inducement material to Mr. Cox’s acce

GlobeNewswire last month

DYN
+4.37%
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Wildon Farwell, M.D., MPH, chief medical officer, and Oxana Beskrovnaya, Ph.D., chief scientific officer, are scheduled to participate in a fireside chat during the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024

GlobeNewswire last month

DYN
+4.37%
Dyne Therapeutics Announces CEO Transition

John Cox John Cox, President and CEO of Dyne Therapeutics - John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of John Cox as president, chief executive off

GlobeNewswire last month

DYN
+4.37%
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days

WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 at 8:30 a.m. ET. A live webcast will be available in the Investors & Media section of Dyne’s website at https:/

GlobeNewswire last month

DYN
+4.37%
Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ...

Key Clinical Trials Show Promise as Company Strengthens Financial Position

GuruFocus.com last month

DYN
+4.37%
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

- Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrated Proof-of-Concept, Validating the Promise of the FORCE™ Platform and Targeted Delivery to Muscle - - Strengthened Balance Sheet with $345 Million Public Offering Extending Projected Cash Runway Through 2025 - WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transformi

GlobeNewswire last month

DYN
+4.37%
CEO & President Joshua Brumm Sells 100,000 Shares of Dyne Therapeutics Inc (DYN)

Joshua Brumm, CEO & President of Dyne Therapeutics Inc (NASDAQ:DYN), has sold 100,000 shares of the company on March 1, 2024, according to a recent SEC Filing.

GuruFocus.com last month

DYN
+4.37%
14 Stocks With Heavy Insider Buying In 2024

In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For a quick overview of such stocks, read our article 5 Stocks With Heavy Insider Buying In 2024. Markets await latest inflation numbers and the debate regarding soft vs hard landing is expected to persist in the Wall Street for months […]

Insider Monkey last month

SANA

TNYA

VOXX
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

- Presentations will Highlight Initial Data Announced in January 2024 Demonstrating Proof-of-Concept in its DM1 and DMD Programs, Validating the Promise of the FORCE™ Platform and Targeted Delivery to Muscle - - Additional Data from ACHIEVE and DELIVER Trials Expected in the Second Half of 2024 - WALTHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people

GlobeNewswire 2 months ago

DYN
+4.37%
Dyne Therapeutics to Present at February Investor Conferences

WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in February: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference, fireside chat on Thursday, February 8, 2024 at 11:00 a.m. ET in New York Oppenheim

GlobeNewswire 2 months ago

DYN
+4.37%
Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN)

Jonathan Mcneill, Chief Business Officer of Dyne Therapeutics Inc (NASDAQ:DYN), executed a sale of 20,000 shares in the company on January 26, 2024, according to a recent SEC Filing.

GuruFocus.com 2 months ago

DYN
+4.37%
7 Speculative Stocks to Double Your Money THIS Year

While investors should probably direct the majority of their market-earmarked funds toward slow-and-steady ideas – à la Warren Buffett – sometimes, we end up with gambling money. And in that case, speculative stocks to double your money might make sense. To be 100% clear, anytime investors venture into high-risk, high-reward stocks, there’s a reason for the warning. Mainly, when market participants buy established blue chips, they’re paying a premium for the predictability. It’s like paying for

InvestorPlace 3 months ago

CRNT

DYN
+4.37%
CAN
Institutional owners may ignore Dyne Therapeutics, Inc.'s (NASDAQ:DYN) recent US$56m market cap decline as longer-term profits stay in the green

Key Insights Institutions' substantial holdings in Dyne Therapeutics implies that they have significant influence over...

Simply Wall St. 3 months ago

DYN
+4.37%
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the closing of its previously announced underwritten public offering of 19,722,500 shares of its common stock at a public offering price of $17.50 per share, which includes 2,572,500 shares issued upon the exercise in full by the underwriter

GlobeNewswire 3 months ago

DYN
+4.37%
CEO & President Joshua Brumm Sells 269,719 Shares of Dyne Therapeutics Inc (DYN)

Joshua Brumm, CEO & President of Dyne Therapeutics Inc (NASDAQ:DYN), executed a sale of 269,719 shares in the company on January 4, 2024, according to a recent SEC Filing.

GuruFocus.com 3 months ago

DYN
+4.37%
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 2:15 p.m. PT (5:15 p.m. ET). A live webcast will be avail

GlobeNewswire 3 months ago

DYN
+4.37%
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 17,150,000 shares of its common stock at a public offering price of $17.50 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and

GlobeNewswire 3 months ago

DYN
+4.37%
Dyne Therapeutics Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has commenced an underwritten public offering of $175,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of its common stock. All

GlobeNewswire 3 months ago

DYN
+4.37%
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown - - All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101 Q4W Demonstrated Consistent Splicing Correction with a 19% Mean Improvement Across 22-Gene Panel at 3 Months - - Improvement in Myotonia (vHOT) as well as Fatigue (MDHI) Observed in Lowest Dose ACHIEVE Cohort at 6 Months - - In Phase 1/2 DELIVER Trial, DYNE-251 Showed 0.88% Mean Dystrophin Expression at

GlobeNewswire 3 months ago

DYN
+4.37%
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials

WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to report initial clinical data from its Phase 1/2 ACHIEVE and DELIVER trials on January 3, 2024, and to host a virtual event at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Dyne’s lea

GlobeNewswire 3 months ago

DYN
+4.37%

Performance Overview

Return	DYN	S&P 500
YTD	+85.94%	+6.92%
1-Year	+132.42%	+25.26%
3-Year	+34.40%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Dyne Therapeutics, Inc. (DYN)

Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

Dyne Therapeutics Announces CEO Transition

Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days

Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ...

Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

CEO & President Joshua Brumm Sells 100,000 Shares of Dyne Therapeutics Inc (DYN)

14 Stocks With Heavy Insider Buying In 2024

Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

Dyne Therapeutics to Present at February Investor Conferences

Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN)

7 Speculative Stocks to Double Your Money THIS Year

Institutional owners may ignore Dyne Therapeutics, Inc.'s (NASDAQ:DYN) recent US$56m market cap decline as longer-term profits stay in the green

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

CEO & President Joshua Brumm Sells 269,719 Shares of Dyne Therapeutics Inc (DYN)

Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases

Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials

Performance Overview